ArticleThe Eurasian journal of medicine2026
Mitochondrial DNA Content Modulates Chemosensitivity and Cellular Adaptation in Glioblastoma Cells.
Article in The Eurasian journal of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMitochondrial DNA (mtDNA) copy number alterations are closely associated with glioblastoma (GBM) progression and therapeutic resistance. This study investigates how changes in mitochondrial content affect the chemotherapeutic response of GBM cells in vitro.
methodsGlioblastoma cell lines (U87 and LN18) were initially treated with ethidium bromide (EtBr) to deplete mtDNA, followed by EtBr withdrawal to enable mtDNA restoration. Real-time Polymerase Chain Reaction (PCR) was subsequently employed to quantify mtDNA levels. To assess cellular responses, cell viability was measured using the CCK-8 assay, while wound healing and Transwell assays were conducted to evaluate cell migration and invasion. Apoptosis was analyzed via flow cytometry using the Annexin V-FITC/ PI kit. In addition, intracellular reactive oxygen species (ROS) and mitochondrial membrane potential (ΔΨm) were examined by flow cytometry, and Adenosine triphosphate (ATP) levels were quantified using a luminescent ATP detection assay.
resultsGlioblastoma cells with depleted mtDNA exhibited an increase in mtDNA content following temozolomide (TMZ) exposure. Despite this, these cells showed reduced viability, migration, and invasion, while also displaying adaptive responses suggestive of emerging resistance. In contrast, cells in which mtDNA content had been restored demonstrated recovery across all parameters, indicating enhanced sensitivity to TMZ.
conclusionThis study highlights the essential role of mtDNA content in modulating GBM cell sensitivity to chemotherapy, as variations in mtDNA levels can influence cellular responses to treatment. These findings suggest that mtDNA content could act as a potential biomarker and that its modulation may offer a promising strategy to overcome drug resistance in GBM. Cite this article as: Radzak SMA, Patar A, Lee H, Yusoff AAM. Mitochondrial DNA content modulates chemosensitivity and cellular adaptation in glioblastoma cells. Eurasian J Med. 2026, 58(2), 1207, doi: 10.5152/eurasianjmed.2026.251207.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.